MedTrace Logo

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

NCT00785538 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.

Conditions

Interventions

BIOLOGICAL

IMC-A12

Cohort 1 3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

IMC-A12

Cohort 2 6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

IMC-A12

Cohort 3 10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

IMC-A12

Cohort 4 15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

IMC-A12

Cohort 5 21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

IMC-A12

Cohort 6 27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785538 on ClinicalTrials.gov